Screening of Lifestyle mitigated Circadian disruptions in metabolic diseases and Differential Effect of Plant derived Omega 3 ALA, DHA & Palmitate blend supplementation on Circadian pattern of Metabolic markers - Omega Alive Study

Indian Council of Medical Research0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年1月9日

试验速览

暂无简介。

•Male Female subjects aged 25 to 60 years
•Clinically stable for at least 6 months
•Capable of giving written informed consent and able to understand and comply with protocol requirements, instructions, and protocol-stated restrictions

•Inability to give consent
•Pregnant or breast-feeding.
•Evidence of clinical instability or abnormal clinical laboratory findings prior to randomization that, in the opinion of the Investigator, makes the subject unsuitable for the study.
•Exposure to substantial radiation within the past 12 months.
•Planned cardiac surgery (e.g., CABG, valve repair or replacement), PCI or major non-cardiac surgery within the study period.
•Diabetics taking injectable insulin at screening.
•Current life-threatening condition other than vascular disease (e.g., very severe chronic airways disease, HIV positive, life-threatening arrhythmias) that may prevent a subject from completing the study.
•Any other subject the Investigator deems unsuitable for the study (e.g., due to either medical reason, laboratory abnormalities, expected study medication non-compliance, inability to medically tolerate the procedures or subjectâ??s unwillingness to comply with all study-related procedures).

发起方